Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

Pericytic tumors of the kidney-a clinicopathologic analysis of 17 cases.

Sirohi D, Smith SC, Epstein JI, Balzer BL, Simko JP, Balitzer D, Benhamida J, Kryvenko ON, Gupta NS, Paluru S, da Cunha IW, Leal DN, Williamson SR, de Peralta-Venturina M, Amin MB.

Hum Pathol. 2017 Jun;64:106-117. doi: 10.1016/j.humpath.2017.04.005. Epub 2017 Apr 21.

PMID:
28438616
6.
8.

Improving the evaluation and diagnosis of clinically significant prostate cancer.

Kryvenko ON, Epstein JI.

Curr Opin Urol. 2017 May;27(3):191-197. doi: 10.1097/MOU.0000000000000388.

PMID:
28376512
9.

Microsurgical identification and excision of an intratesticular mass.

Sávio LF, Prakash NS, Clavijo R, Kryvenko ON, Ramasamy R.

Fertil Steril. 2017 Apr;107(4):e16. doi: 10.1016/j.fertnstert.2017.01.012. Epub 2017 Feb 24.

PMID:
28238493
10.

Editorial Comment.

Kryvenko ON.

J Urol. 2017 May;197(5):1235-1236. doi: 10.1016/j.juro.2016.12.126. Epub 2017 Feb 9. No abstract available.

PMID:
28189556
12.

Understanding PSA and its derivatives in prediction of tumor volume: Addressing health disparities in prostate cancer risk stratification.

Chinea FM, Lyapichev K, Epstein JI, Kwon D, Smith PT, Pollack A, Cote RJ, Kryvenko ON.

Oncotarget. 2017 Mar 28;8(13):20802-20812. doi: 10.18632/oncotarget.14903.

13.

Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study.

von Rundstedt FC, Mata DA, Kryvenko ON, Shah AA, Jhun I, Lerner SP.

Bladder Cancer. 2017 Jan 27;3(1):35-44. doi: 10.3233/BLC-160062.

14.

In Reply.

Epstein JI, Kryvenko ON.

Arch Pathol Lab Med. 2017 Feb;141(2):183-184. doi: 10.5858/arpa.2016-0434-LE. No abstract available.

PMID:
28134584
15.

Diagnostic pitfalls of infarcted Warthin tumor in frozen section evaluation.

Tan Y, Kryvenko ON, Kerr DA, Chapman JR, Kovacs C, Arnold DJ, Rosenberg AE, Gomez-Fernandez CR.

Ann Diagn Pathol. 2016 Dec;25:26-30. doi: 10.1016/j.anndiagpath.2016.08.004. Epub 2016 Aug 20.

PMID:
27806841
16.

Adaptation to Stressors by Systemic Protein Amyloidogenesis.

Audas TE, Audas DE, Jacob MD, Ho JJ, Khacho M, Wang M, Perera JK, Gardiner C, Bennett CA, Head T, Kryvenko ON, Jorda M, Daunert S, Malhotra A, Trinkle-Mulcahy L, Gonzalgo ML, Lee S.

Dev Cell. 2016 Oct 24;39(2):155-168. doi: 10.1016/j.devcel.2016.09.002. Epub 2016 Oct 6.

PMID:
27720612
17.
18.

Definition of Insignificant Tumor Volume of Gleason Score 3 + 3 = 6 (Grade Group 1) Prostate Cancer at Radical Prostatectomy-Is it Time to Increase the Threshold?

Kryvenko ON, Epstein JI.

J Urol. 2016 Dec;196(6):1664-1669. doi: 10.1016/j.juro.2016.06.013. Epub 2016 Jun 9.

PMID:
27291653
19.

Small cell-like glandular proliferation of prostate: a rare lesion not related to small cell prostate cancer.

Kryvenko ON, Williamson SR, Trpkov K, Gupta NS, Athanazio D, Selig MK, Smith PT, Magi-Galluzzi C, Jorda M.

Virchows Arch. 2017 Jan;470(1):47-54. doi: 10.1007/s00428-016-2033-7. Epub 2016 Oct 14.

PMID:
27743032
20.

A Limited Immunohistochemical Panel to Distinguish Basal Cell Carcinoma of Cutaneous Origin From Basaloid Squamous Cell Carcinoma of the Head and Neck.

Villada G, Kryvenko ON, Campuzano-Zuluaga G, Kovacs C, Chapman J, Gomez-Fernandez C.

Appl Immunohistochem Mol Morphol. 2016 Jul 19. [Epub ahead of print]

PMID:
27438511

Supplemental Content

Loading ...
Support Center